Phathom Pharmaceuticals (PHAT)

Phathom markets vonoprazan in the United States under the VOQUEZNA brand and develops it across indications such as gastroesophageal reflux disease, erosive esophagitis, and Helicobacter pylori infection. For H. pylori, vonoprazan is used with antibiotics as part of combination regimens intended to eradicate the bacteria, a major cause of ulcers and other upper gastrointestinal complications. In reflux disease, the company targets a large market of patients who may need consistent acid suppression to manage symptoms and promote healing.

The company’s strategy centers on establishing vonoprazan as a differentiated therapy in a mature but substantial GI drug market. Phathom’s commercial opportunity depends on physician adoption, payer coverage, patient access, and its ability to demonstrate practical advantages over existing acid-suppressive medicines. As a biotechnology stock, PHAT is closely tied to regulatory milestones, clinical data, prescription trends, and commercialization execution. Its appeal to investors comes from the combination of a focused product platform, a large addressable gastrointestinal market, and the potential for vonoprazan to become a meaningful alternative in acid-related disease care.